136 related articles for article (PubMed ID: 36333130)
21. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
[TBL] [Abstract][Full Text] [Related]
22. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
[TBL] [Abstract][Full Text] [Related]
23. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
24. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT assessment of histopathologically confirmed mediastinal lymph nodes in non-small cell lung cancer using a penalised likelihood reconstruction.
Teoh EJ; McGowan DR; Bradley KM; Belcher E; Black E; Moore A; Sykes A; Gleeson FV
Eur Radiol; 2016 Nov; 26(11):4098-4106. PubMed ID: 26914696
[TBL] [Abstract][Full Text] [Related]
26. Determination of optimal regularization factor in Bayesian penalized likelihood reconstruction of brain PET images using [
Wagatsuma K; Miwa K; Kamitaka Y; Koike E; Yamao T; Yoshii T; Kobayashi R; Nezu S; Sugamata Y; Miyaji N; Imabayashi E; Ishibashi K; Toyohara J; Ishii K
Med Phys; 2022 May; 49(5):2995-3005. PubMed ID: 35246870
[TBL] [Abstract][Full Text] [Related]
27. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
[TBL] [Abstract][Full Text] [Related]
28. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
29. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
30. Novel penalised likelihood reconstruction of PET in the assessment of histologically verified small pulmonary nodules.
Teoh EJ; McGowan DR; Bradley KM; Belcher E; Black E; Gleeson FV
Eur Radiol; 2016 Feb; 26(2):576-84. PubMed ID: 25991490
[TBL] [Abstract][Full Text] [Related]
31. Bayesian penalized likelihood PET reconstruction impact on quantitative metrics in diffuse large B-cell lymphoma.
Young JR; Mugu VK; Johnson GB; Ehman EC; Packard AT; Homb AC; Nathan MA; Thanarajasingam G; Kemp BJ
Medicine (Baltimore); 2023 Feb; 102(6):e32665. PubMed ID: 36820562
[TBL] [Abstract][Full Text] [Related]
32. Ordered subset expectation maximisation vs Bayesian penalised likelihood reconstruction algorithm in 18F-PSMA-1007 PET/CT.
Witkowska-Patena E; Budzyńska A; Giżewska A; Dziuk M; Walęcka-Mazur A
Ann Nucl Med; 2020 Mar; 34(3):192-199. PubMed ID: 31902120
[TBL] [Abstract][Full Text] [Related]
33. Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?
Chiaravalloti A; Pagani M; Di Pietro B; Danieli R; Tavolozza M; Travascio L; Caracciolo CR; Simonetti G; Cantonetti M; Schillaci O
Nucl Med Commun; 2013 Jan; 34(1):57-63. PubMed ID: 23104001
[TBL] [Abstract][Full Text] [Related]
34. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
35. Bayesian penalised likelihood reconstruction (Q.Clear) of
Teoh EJ; McGowan DR; Schuster DM; Tsakok MT; Gleeson FV; Bradley KM
Br J Radiol; 2018 May; 91(1085):20170727. PubMed ID: 29303359
[TBL] [Abstract][Full Text] [Related]
36. Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
Biggi A; Chauvie S; Fallanca F; Guerra L; Bergesio F; Menga M; Bianchi A; Gregianin M; Chiaravalloti A; Schillaci O; Pavoni C; Patti C; Picardi M; Romano A; Schiavotto C; Sorasio R; Viviani S; La Nasa G; Trentin L; Rambaldi A; Gallamini A
Hematol Oncol; 2023 Aug; 41(3):415-423. PubMed ID: 36534947
[TBL] [Abstract][Full Text] [Related]
37. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study.
Durmo R; Donati B; Rebaud L; Cottereau AS; Ruffini A; Nizzoli ME; Ciavarella S; Vegliante MC; Nioche C; Meignan M; Merli F; Versari A; Ciarrocchi A; Buvat I; Luminari S
Hematol Oncol; 2022 Oct; 40(4):645-657. PubMed ID: 35606338
[TBL] [Abstract][Full Text] [Related]
39. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
[TBL] [Abstract][Full Text] [Related]
40. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.
Zinzani PL; Rigacci L; Stefoni V; Broccoli A; Puccini B; Castagnoli A; Vaggelli L; Zanoni L; Argnani L; Baccarani M; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):4-12. PubMed ID: 21894546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
